

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Cost Comaprison Appraisal

Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over [ID6372]

Final Stakeholder List

Provisional Consultees Provisional Commentators (no right to	
Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
 Vertex Pharmaceuticals 	All Wales Therapeutics and Toxicology
(deutivacaftor, tezacaftor, vanzacaftor)	Centre
	 Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
 Asthma and Lung UK 	Wales
CF Voices	British National Formulary
Cystic Fibrosis Care	Care Quality Commission
Cystic Fibrosis Trust	Department of Health - Northern Ireland
Gene People	Healthcare Improvement Scotland
Genetic Alliance	Medicines and Healthcare products
 NARA – The Breathing Charity 	Regulatory Agency
South Asian Health Foundation	National Association of Primary Care
Specialised Healthcare Alliance	National Pharmacy Association
·	NHS Confederation
Healthcare professional groups	NHS Wales Joint Commissioning
 Association for Respiratory 	Committee
Technology and Physiology	Scottish Medicines Consortium
 Association of Chartered 	Welsh Government
Physiotherapists in Cystic Fibrosis	
 Association of Genetic Nurses and 	Comparator companies
Counsellors	 Vertex Pharmaceuticals (elexacaftor,
 Association of Respiratory Nurse 	lumcaftor and ivacaftor)
Specialists	
British Dietetic Association	Relevant research groups
British Geriatrics Society	 British Association for Lung Research
 British Inherited Metabolic Disease 	CF Health Hub
Group	Cochrane Airways Group
 British Paediatric Respiratory Society 	Cochrane Cystic Fibrosis and Genetic
 British Society for Gene and Cell 	Disorders Group
Therapy	Genomics England
 British Society for Genetic Medicine 	MRC Clinical Trials Unit
 British Society for Medical Genetics 	National Institute for Health Research
British Thoracic Society	UK Cystic Fibrosis Gene Therapy
 Chartered Society of Physiotherapy 	Consortium
Cystic Fibrosis Nursing Association	

Final stakeholder list for the evaluation of vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over [ID6372] Issue date: January 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 ENT UK Interstitial Lung Diseases Interdisciplinary Network (ILD-IN) National Heart and Lung Institute Neonatal and Paediatric Pharmacists Group (NPPG) Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Paediatrics & Child Health Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Cystic Fibrosis Medical Association UK Cystic Fibrosis Pharmacy Group UK Psychosocial Professionals in Cystic Fibrosis Group Others Department of Health and Social Care NHS England 	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over [ID6372] Issue date: January 2025



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.